Back to top
more

RA PHARMCTL INC (RARX)

(Delayed Data from NSDQ)

$21.94 USD

21.94
271,273

-0.22 (-0.99%)

Updated May 3, 2019 04:00 PM ET

After-Market: $21.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (RARX) Outperforming Other Medical Stocks This Year?

How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Ra Pharmaceuticals (RARX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

by Zacks Equity Research

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

Company News For Oct 11, 2019

by Zacks Equity Research

Companies in the news are: RARX, BBBY, PCG, MITO

Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA

by Zacks Equity Research

Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).

Sweta Killa headshot

Best ETFs & Stocks From the Top Sector of Q3

by Sweta Killa

Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

    Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?

    by Zacks Equity Research

    Ra Pharmaceuticals, Inc. (RARX) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA.

      RA PHARMCTL INC (RARX) Sees Hammer Chart Pattern: Time to Buy?

      by Zacks Equity Research

      RA PHARMCTL has been struggling lately, but the selling pressure may be coming to an end soon.